133 related articles for article (PubMed ID: 843215)
1. Effectiveness of systemic BCG therapy in advanced melanoma.
El-Domeiri AA; Nika B; Hsia WC; Crispen R; Sabet TY; Gupta TK
Arch Surg; 1977 Mar; 112(3):257-9. PubMed ID: 843215
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
[TBL] [Abstract][Full Text] [Related]
3. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
Peter HH; Deutschmann EM; Schultheis W; Deicher H
Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
[TBL] [Abstract][Full Text] [Related]
4. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
Lieberman R; Wybran J; Epstein W
Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
[TBL] [Abstract][Full Text] [Related]
5. BCG immunotherapy in patients with malignant melanoma.
Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
[TBL] [Abstract][Full Text] [Related]
6. Immune response and non-specific immunotherapy in melanoma.
El-Domeiri AA
Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.
McKhann CF; Hendrickson CG; Spitler LE; Gunnarsson A; Banerjee D; Nelson WR
Cancer; 1975 Feb; 35(2):514-20. PubMed ID: 234291
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
[TBL] [Abstract][Full Text] [Related]
10. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases.
Morton DL; Eilber FR; Holmes EC; Ramming KP
Aust N Z J Surg; 1978 Feb; 48(1):49-52. PubMed ID: 276348
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
[TBL] [Abstract][Full Text] [Related]
12. Results of adjuvant BCG immunotherapy in malignant melanoma.
Wätzig V; Knopf B
Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
[TBL] [Abstract][Full Text] [Related]
13. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.
Mastrangelo MJ; Bellet RE; Berkelhammer J; Clark WH
Cancer; 1975 Oct; 36(4):1305-8. PubMed ID: 1175129
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
[TBL] [Abstract][Full Text] [Related]
15. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
Deutschmann KE; Peter HH; Schultheis W; Deicher H
Tumori; 1977; 63(3):303-7. PubMed ID: 898298
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
Front Immunol; 2018; 9():411. PubMed ID: 29552014
[TBL] [Abstract][Full Text] [Related]
17. Intralesional immunotherapy of melanoma with BCG.
Rosenberg SA; Rapp HJ
Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
[TBL] [Abstract][Full Text] [Related]
18. The use of oral BCG in the treatment or metastatic malignant melanoma.
Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
[TBL] [Abstract][Full Text] [Related]
19. Results of administering B.C.G. to patients with melanoma.
Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
[No Abstract] [Full Text] [Related]
20. Mumps virus and BCG vaccine in metastatic melanoma.
Minton JP
Arch Surg; 1973 Apr; 106(4):503-6. PubMed ID: 4572347
[No Abstract] [Full Text] [Related]
[Next] [New Search]
